Tacrolimus alleviates pulmonary fibrosis progression through inhibiting the activation and interaction of ILC2 and monocytes

This study will reveal the specific process of tacrolimus alleviating pulmonary fibrosis by regulating type II immunity, and explore the potential feasibility of tacrolimus combined with nintedanib in the treatment of pulmonary fibrosis. This project will provide new ideas for clinical optimization of anti-pulmonary fibrosis drug strategies.PMID:38581994 | DOI:10.1016/j.intimp.2024.111999

Source: International Immunopharmacology - April 6, 2024 Category: Allergy & Immunology Authors: Bowen Liu Qiuyan Jiang Ruxuan Chen Huizhe Zhang Qin Xia Chi Shao Xiangning Liu Mengqi Wang Yujie Shi Jingyan Zhu Ruixi Zhao Haixia Jiang Shaoyan Gao Xiaohe Li Honggang Zhou Cheng Yang Hui Huang Source Type: research